Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · Real-Time Price · USD
71.56
+1.38 (1.97%)
At close: Jul 21, 2025, 4:00 PM
71.56
0.00 (0.00%)
After-hours: Jul 21, 2025, 4:20 PM EDT
Lantheus Holdings Revenue
Lantheus Holdings had revenue of $372.76M in the quarter ending March 31, 2025, with 0.75% growth. This brings the company's revenue in the last twelve months to $1.54B, up 12.53% year-over-year. In the year 2024, Lantheus Holdings had annual revenue of $1.53B with 18.32% growth.
Revenue (ttm)
$1.54B
Revenue Growth
+12.53%
P/S Ratio
3.16
Revenue / Employee
$1,901,855
Employees
808
Market Cap
4.95B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.53B | 237.48M | 18.32% |
Dec 31, 2023 | 1.30B | 361.37M | 38.65% |
Dec 31, 2022 | 935.06M | 509.85M | 119.91% |
Dec 31, 2021 | 425.21M | 85.80M | 25.28% |
Dec 31, 2020 | 339.41M | -7.93M | -2.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LNTH News
- 7 hours ago - Lantheus Holdings: Forget The Short Term Noise - Seeking Alpha
- 5 days ago - Why Is Lantheus Stock Trading Lower On Wednesday? - Benzinga
- 20 days ago - Lantheus Seems Worth The (Very Real) Risks - Seeking Alpha
- 5 weeks ago - Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Lantheus to Present at the 2025 Truist Securities MedTech Conference - GlobeNewsWire
- 7 weeks ago - PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer - PRNewsWire
- 2 months ago - Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy - Seeking Alpha
- 2 months ago - Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH - PRNewsWire